DNA vaccine technology is a third-generation vaccine technology that introduces host animal with a genetic material of disease-causing pathogen. This genetic material helps to strengthen the immune system by forming a protective protein that enables effective immune response against a disease-causing antigen. Global DNA vaccine market is anticipated to rise with a CAGR of about 55% during the forecast years 2016-2023. Increasing adoption of DNA vaccines for animal healthcare is driving the global DNA vaccines market. Some other factors that includes rising prevalence of chronic and infectious diseases, surging investments in the development of third generation vaccination technology and low cost of DNA vaccines as compared to other gene therapy technologies also helps to drive the market growth.

The global DNA vaccine market is segmented on the basis of geography into North America, Europe, Asia Pacific and rest of the world. Asia pacific market is estimated to grow at a fast pace as compared to other regions due to rising awareness among consumers regarding the advantages of immunization in case of H1N1 influenza and Hepatitis B. For instance, State food and drug administration in China has designated 11 biotech companies for the development of H1N1 influenza vaccine. North America region dominates the majority of market revenue among other regions. Increasing prevalence of infectious and chronic diseases in countries such as US and Canada is driving the demand of effective vaccination technology. Mortality rate due to chronic and infectious disease has increased in the United States to about 360,000 every year.

The global DNA vaccine market has been segmented on the basis of type of DNA vaccines, technology and applications. On the basis of application, the market has been segmented into human disease applications and veterinary disease applications market. Among these, the veterinary applications are leading the DNA vaccine market due to availability of DNA vaccines for animal diseases that includes canine melanoma vaccine (for DOG), West Nile Innovator (for Horse), Life tide-SW5 (for Swine and other food animals) and Apex-IHN (for Salmon fish). Among the segment of DNA vaccine type, Animal DNA vaccine is a leading the market due to unavailability of human DNA vaccines in the market along with rising incidence of canine melanoma and other animal diseases. Canine melanoma accounts to about 7% of all canine skin tumours cases globally. Moreover, after the entry of human DNA vaccines, this segment is expected to grow at a fast pace.

The major market players of the global DNA vaccine market include Novartis Animal Health, Inovio Biomedical Corp., Merck & Co., Vical Inc., Dendreon Corporation, Astellas Pharma, Sanofi, Tekmira Pharmaceuticals, GlaxoSmithKline Inc., Pfizer Pharmaceuticals, Advance Bioscience Laboratories Inc., Indian Immunologicals Ltd., Xenetic Biosciences Inc., QED Biosciences Inc., Tolerion Inc. and Others. These companies using various strategies such as merger & acquisition, collaboration, partnership and product launch. Whereas, merger & acquisition is the key strategy adopted by the companies in the global DNA vaccine market.

For example, On 14th January 2015, Vical and AnGes announced a collaboration for the development of Ebola virus disease therapy. Vical will develop and provide a DNA vaccine by encoding the glycoprotein antigen of zaire strain of Ebola virus to AnGes. Vical’s proprietary Vaxfectin? adjuvant will help in the formulation of vaccine. AnGes will be granted with the right regarding development and commercialization of the equine polyclonal antibody therapy in Japan and will bear all the development costs. Vical will be receiving an upfront payment and royalties on net sales.